ALKINDI
Total Payments
$196,346
Transactions
734
Doctors
378
Companies
2
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $79,864 | 124 | 124 |
| 2023 | $98,125 | 219 | 219 |
| 2022 | $18,357 | 391 | 148 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $155,101 | 23 | 79.0% |
| Food and Beverage | $39,728 | 411 | 20.2% |
| Education | $1,518 | 300 | 0.8% |
Ad
Manufacturing Companies
- Eton Pharmaceuticals, Inc. $193,760
- TOLMAR Pharmaceuticals, Inc. $2,586
Product Information
- Type Drug
- Total Payments $196,346
- Total Doctors 378
- Transactions 734
About ALKINDI
ALKINDI is a drug associated with $196,346 in payments to 378 healthcare providers, recorded across 734 transactions in the CMS Open Payments database. The primary manufacturer is Eton Pharmaceuticals, Inc..
Payment data is available from 2022 to 2024. In 2024, $79,864 was paid across 124 transactions to 124 doctors.
The most common payment nature for ALKINDI is "Consulting Fee" ($155,101, 79.0% of total).